RxDoctor Payments Data

Amanda Smith, PA

Physician Assistant · Lancaster, OHNPI 1508467010

Payments from drug & device makers

$2,775in general payments, 2019–2025

Across 141 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$630
  • Regeneron Healthcare Solutions, Inc.$377
  • AbbVie$350
  • UCB, Inc.$205
  • Amgen$166
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • plus $922 from 21 others

What the payments were for

  • Food & beverage$2,34885%
  • Education$42615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,775 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$61,717
Medicare patients
386
Services billed
1,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab27$101,246
OpzeluraRuxolitinib Phosphate16$35,579
Tacrolimus14$2,266
Ketoconazole152$1,887
Metronidazole21$1,767
Clobetasol Propionate37$1,590
Triamcinolone Acetonide92$1,560
Fluorouracil16$1,369
Fluocinonide34$1,308
Minocycline Hcl18$468
Doxycycline Hyclate14$427
Clindamycin Phosphate11$383
Mupirocin28$142
Hydrocortisone15$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$82$35,57916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →